|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, ectopic expression of DUB3 caused NRF2-dependent chemotherapy resistance in colon cancer cell lines.
|
30778200 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, to the best of our knowledge, our findings are the first to identify DUB3 as a NRF2 DUB and may provide a new strategy against chemotherapy resistance in CRC and other NRF2-related diseases.
|
30778200 |
2019 |
|
Endometriosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Whole exome sequencing identifies hemizygous deletions in the UGT2B28 and USP17L2 genes in a three‑generation family with endometriosis.
|
30628680 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases.
|
31534019 |
2019 |
|
Colon Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, ectopic expression of DUB3 caused NRF2-dependent chemotherapy resistance in colon cancer cell lines.
|
30778200 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer.
|
30778200 |
2019 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
USP17 expression in lung cancers was associated with poor prognosis, macrophage, and inflammatory marker expressions.
|
30038267 |
2018 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study shows that USP17 enhances osteosarcoma cell proliferation and invasion through stabilizing SMAD4.
|
28670958 |
2017 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study shows that USP17 enhances osteosarcoma cell proliferation and invasion through stabilizing SMAD4.
|
28670958 |
2017 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, this study shows that USP17 enhances osteosarcoma cell proliferation and invasion through stabilizing SMAD4.
|
28670958 |
2017 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
USP17 was more highly expressed in low grade (I+II) glioma than high-grade (III+IV) glioma (p<0.001).
|
26777424 |
2016 |
|
Childhood Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Adult Solid Neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Solid Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
USP17 is a novel deubiquitinating enzyme that is differentially expressed in certain types of solid tumor.
|
26777424 |
2016 |
|
Cystadenoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High levels of Dub3 expression were examined by immunohistochemical analysis in 13.3% of cystadenomas, in 30.0% of borderline tumors, and in 58.9% of ovarian carcinomas, respectively.
|
25776484 |
2015 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer.
|
25776484 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Dub3 expression was significantly associated with lymph node metastasis and clinical staging (P<0.05).
|
25776484 |
2015 |
|
Glucocorticoid Receptor Deficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Small molecules which can specifically induce the expression of USP17 might be useful in reversing glucocorticoid resistance.
|
26617781 |
2015 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, USP17 expression was up-regulated in CD4(+) T cells from systemic lupus erythematosus patients.
|
25070893 |
2014 |
|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
USP17 was overexpressed in both squamous and adenocarcinoma NSCLC tissue.
|
24123619 |
2013 |
|
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, these findings establish USP17 as a potentially valuable novel biomarker for metastatic lung cancer.
|
24123619 |
2013 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.
|
30906206 |
2019 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
Altogether, our results revealed the essential role of the MGMT-DUB3-MCL1 axis in the chemoresistance of ovarian cancer and identified that a combined treatment with HDACis and PaTrin-2 is an effective method for overcoming chemoresistance in ovarian cancer.
|
30718431 |
2019 |